Public hearings as a transparency measure: The Valproate case

TY - ABST

T1 - Public hearings as a transparency measure: The Valproate case

AU - Møllebæk, Mathias

PY - 2017/10/2

Y1 - 2017/10/2

N2 - In line with increasing calls of transparency initiatives across European institutions, the European Medicines Agency (EMA) will on September 26th 2017 host its first public hearing on the regulatory of a drug, namely Valproate. According to the EMA website, the public hearing is intended to “increase transparency by opening up the scientific evaluation process” and “[give citizens] a voice in the evaluation of medicines.” This conference paper will present the preliminary results from a rhetorical analysis of the public hearing as a transparency measure. What kind transparency does a public hearing provide? How are citizens’ accounts positioned vis-à-vis expert testimonies? Does the public hearing achieve sufficient “hybridity” of its heterogeneous stakeholder group?

AB - In line with increasing calls of transparency initiatives across European institutions, the European Medicines Agency (EMA) will on September 26th 2017 host its first public hearing on the regulatory of a drug, namely Valproate. According to the EMA website, the public hearing is intended to “increase transparency by opening up the scientific evaluation process” and “[give citizens] a voice in the evaluation of medicines.” This conference paper will present the preliminary results from a rhetorical analysis of the public hearing as a transparency measure. What kind transparency does a public hearing provide? How are citizens’ accounts positioned vis-à-vis expert testimonies? Does the public hearing achieve sufficient “hybridity” of its heterogeneous stakeholder group?

M3 - Conference abstract for conference

ER -